The TSO 500 HRD research test aligns Myriad's gold standard MyChoice® CDx HRD technology with Illumina's pan-cancer test, TSO 500. The test was codeveloped with Merck (known as MSD outside the US and ...
SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...
A community-based study found that despite current guidelines recommending that all patients diagnosed with epithelial ovarian cancer undergo testing for homologous repair deficiency (HRD), only about ...
Germline genetic testing for patients with gynecologic cancers can be conducted in parallel with tumor somatic testing via a targeted sequencing assay by primary oncologists, researchers reported.
Targeting ALKBH5 with cisplatin-Ga nanodrug to investigate platinum sensitivity in resistant ovarian cancer through m6A-dependent mechanisms. Intermittent PARP inhibitor regimen in ovarian cancer ...
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results